It is important for biologists to select the most accurate cell counting method that is fit-for-purpose, especially for cellular therapy products such as CAR T, where cell number and viability significantly affect treatment efficacy.
The use of modern automation has largely eliminated many of the hemocytometer's sources of error, increasing the accuracy and efficiency of cell counting today.
Nexcelom founder and CTO, Dr. Jean Qiu, describes 3 major reasons why we partner with global and local research organizations to streamline CAR-T workflow.
Q & A regarding the crucial need for accurate and consistent cell counting methods for development and manufacturing of CAR-T under GMP/GLP conditions.
